Search the Newsreel

IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend

IDEAYA Biosciences reported Q2 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, with R&D expenses significantly increasing to $108.7 million for the quarter. The company strengthened its liquidity through a June 2026 follow-on offering and at-the-market sales, boosting cash, …

Uveal melanoma trial reports 6.9 months progression-free vs. 3.1

IDEAYA Biosciences (IDYA) announced positive results from its registrational Phase 2/3 OptimUM-02 trial for darovasertib plus crizotinib in metastatic uveal melanoma, meeting its primary endpoint with a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the investigator's choice arm. The …

Ideal Power Inc (IPWR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ideal Power Inc (IPWR), detailing its current earnings forecast score, price target, and analyst ratings. Based on one analyst, the company has a "Buy" rating with a target price of $10.75, representing a 151.76% upside. The article …

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion

IDEAYA Biosciences (IDYA) reported a Q2 2026 net loss of $112.5 million ($1.22 per share) on collaboration revenue of $8.9 million, up from the prior quarter. The company announced its cash, cash equivalents, and marketable securities reached $1.24 billion, with cash runway guidance into …

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences announced its second-quarter 2026 financial results and provided a business update. The company's registrational OptimUM-02 trial for darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA also reported a strong financial position with approximately $1.24 …

IDEAYA Biosciences reports Q2 2026 net loss $112.5M; cash $1.24B after $323M offering

IDEAYA Biosciences reported a net loss of $112.5 million for Q2 2026, ending the period with $1.24 billion in cash, cash equivalents, and marketable securities after a $323 million public offering. The company's OptimUM-02 trial met its primary endpoint, leading to an NDA filing …

IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises

IDEAYA Biosciences (IDYA) reported a wider loss of $1.22 per diluted share in Q2, compared to the previous quarter. Despite the increased loss, the company experienced a rise in revenue during the same period. This article provides a brief overview of IDEAYA's Q2 financial …

Ideal Power (NASDAQ:IPWR) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

Ideal Power (NASDAQ:IPWR) shares have fallen below their 200-day moving average, trading at $3.87 compared to the average of $4.37. Analyst sentiment is mixed, with a "Hold" consensus and an average price target of $10.75, despite the company missing quarterly earnings expectations. Institutional investors …

ideaForge Technology Q1 Results: Earnings call scheduled for Aug 11

Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M

IDEAYA Biosciences, Inc. (IDYA) announced its Q2 revenue of $8.9 million, surpassing FactSet's estimate of $8.0 million. This news comes alongside other recent updates for the company, including Wedbush adjusting its price target to $60 and maintaining an Outperform rating, and the company's Q2 …

Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA

Dimensional Fund Advisors LP significantly increased its stake in IDEAYA Biosciences, Inc. (IDYA) by 42% in Q1, now holding 1.33 million shares valued at $44.4 million. Other institutional investors like State Street and Janus Henderson also boosted their positions, with institutional ownership reaching 98.29%. …

IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday

XS216184378 Bond Profile — Key Metrics

This article provides key metrics for the AMTD IDEA Group bond, identified by XS216184378. It details the issuer, issue date, outstanding amount, face value, minimum denomination, and a 16.04% coupon rate. The profile also includes a description of AMTD IDEA Group's business segments, such …

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences announced inducement grants of stock options to three new employees. These grants were approved by the Compensation Committee of the company's Board of Directors and are made under Nasdaq Listing Rule 5635(c)(4) as an inducement material to the employees entering into employment …

IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per share

IDEAYA Biosciences issued inducement stock options for 260,200 shares to 14 new employees on July 30, 2026. The exercise price for these options is $36.4 per share, matching the stock's Nasdaq closing price on the grant date. These awards have a 10-year term, with …

14 New IDEAYA Hires Granted Stock Options at $36.40

IDEAYA Biosciences (NASDAQ: IDYA) has granted non-qualified stock options for an aggregate of 260,200 shares to fourteen newly hired employees. These grants were made under the 2023 Employment Inducement Incentive Award Plan, with an exercise price of $36.40 per share, equal to the closing …

Janus Henderson Group PLC Boosts Stake in IDEAYA Biosciences, Inc. $IDYA

Ideal Power to report Q2 2026 earnings on August 13 with live call and webcast.

Ideal Power Inc. is set to release its second-quarter financial results for 2026 on August 13, 2026. The company will host a conference call and webcast at 10:00 AM Eastern Time to discuss these results and provide an outlook. Ideal Power is recognized for …

Ideal Power to Host Second Quarter 2026 Results Conference Call on August 13, 2026 at 10:00 AM Eastern Time

Ideal Power Inc. (Nasdaq: IPWR) announced it will host a conference call on Thursday, August 13, 2026, at 10:00 AM Eastern Time to discuss its second-quarter results for the period ended June 30, 2026. A press release detailing these results will be issued before …

Investors Can Question Ideal Power Management on Aug. 13

Ideal Power (Nasdaq: IPWR) announced it will host a conference call on August 13, 2026, at 10:00 AM Eastern Time to discuss its second-quarter 2026 results. The company, known for its B-TRAN® bidirectional semiconductor power switch, will issue a press release before the call, …

IPWR|Ideal Power Inc|Price:3.330|Chg%:-0.430

This article provides a detailed financial overview of Ideal Power Inc (IPWR), including its income statement, balance sheet, and cash flow statement. It highlights the company's recent earnings, revenue, and EPS forecasts, along with historical quarterly and annual financial indicators. The report also addresses …

AMTD IDEA Group (AMTD) Institutional Confidence

The article evaluates AMTD IDEA Group's institutional confidence, noting a score of 3.00, placing it 70th in its industry. Institutional shareholding increased significantly by 166.19% quarter-over-quarter to 1.29%, with James Simons being the largest institutional shareholder despite a decrease in his holdings. The document …

Will IDEAYA’s (IDYA) IDE892 Combo Strategy in MTAP‑Deleted Cancers Reshape Its Targeted Oncology Narrative?

IDEAYA Biosciences is expanding its Phase 1/2 trial for IDE892, a PRMT5 inhibitor targeting MTAP-deleted solid tumors, into monotherapy expansion. This move positions IDE892 as a combination backbone for various cancer treatments, potentially reshaping IDEAYA's investment narrative by adding a second pillar to its …

Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50

Mizuho Securities has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US), maintaining a target price of $50. This continued endorsement suggests the firm's confidence in the biotechnology company's future performance and valuation. The decision indicates that Mizuho sees strong potential for growth or continued …

AMTD IDEA Group (AMTD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of AMTD IDEA Group (AMTD), detailing its price momentum score, current trading range, and technical indicators. The stock currently has a price momentum score of 4.43 and is trading between a resistance level of 0.93 and a support …

AMTD IDEA Group (AMTD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AMTD IDEA Group (AMTD), noting its current risk assessment score of 2.28, which ranks it 99 out of 118 in the Investment Banking & Investment Services industry. The company's beta of 0.63 suggests it is less volatile …

Ideal Power Inc (IPWR) Financial Health: Profitability & Balance Sheet Analysis

Ideal Power Inc (IPWR) has a current financial score of 6.96, ranking 77 out of 105 in the Semiconductors & Semiconductor Equipment industry, indicating a robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 100.00% year-over-year, and its net …

IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLC

AMTD IDEA Group American Depositary Shares, each representing six (6) Class A Ordinary Shares (NYSE:AMTD) Short Interest Update

AMTD IDEA Group (NYSE:AMTD) experienced a significant 126.9% increase in short interest as of July 15th, rising to 27,754 shares. The stock has a days-to-cover ratio of 5.9 and fell 1.0% to $0.76, trading near its 12-month low and below key moving averages. The …

IDEAYA Biosciences Inc (IDYA) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for IDEAYA Biosciences Inc (IDYA), covering operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures for various cash flow components. The report also features a FAQ section explaining …

IDEAYA Biosciences (IDYA) Advances IDE892 Trial, Is The Upside Already Priced In?

IDEAYA Biosciences (IDYA) has moved its IDE892 trial into Part 2 monotherapy expansion for MTAP-deleted solid tumors, showcasing positive momentum with recent share price gains. While the company's 15.5x price-to-sales ratio is considered overvalued compared to the broader US biotechs industry, it is undervalued …

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences has initiated Part 2 monotherapy expansion of its Phase 1/2 clinical trial for IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor. This expansion focuses on MTAP-deleted solid tumors, specifically non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), building on its unique …

Ideal Power Inc. Revenue Breakdown – DUS:5ILA

Ideal Power Inc. (DUS:5ILA) generated 32.12K EUR in revenue last year, primarily from its Bidirectional Bipolar Junction TRANsistor segment. This revenue figure represents a decrease from the previous year's 83.11K EUR. The United States was the company's largest contributor to revenue.

Ideal Power Inc (IPWR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Ideal Power Inc (IPWR)'s dividend and stock split history, noting that no dividends have been distributed in the past five years. It presents market data for IPWR, including its current stock price, market cap, and P/E TTM. The …

AMTD IDEA Group (AMTD) Balance Sheet